Semaglutide · evidence
Semaglutide evidence: what the STEP trials actually show
The randomized semaglutide evidence, weight-loss figures, maintenance/withdrawal data, and the microdosing gap.
The strongest semaglutide evidence is for the approved product at its labeled dose, chiefly the STEP trial program. In STEP 1, approved semaglutide produced about 14.9% mean weight loss versus roughly 2.4% on placebo. None of these trials studied a compounded product or a deliberate microdose, so the evidence does not transfer to below-label dosing. Compounded semaglutide is not FDA approved.
What the approved-product trials showed
Published mean weight loss, approved semaglutide trials (%) — approved labeled doses only
In STEP 1, approved semaglutide at its labeled dose produced roughly 14.9% mean weight loss over about 68–72 weeks, far above placebo. The STEP 4 withdrawal design tested what happens when treatment continues versus stops, and consistently showed that stopping leads to substantial weight regain — a central fact for anyone thinking about cost and duration.
Beyond weight, the SELECT trial showed about a 20% reduction in major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity, without diabetes — a benefit tied to the approved product and its studied dose, not to compounded or microdose versions.
Trial dataset
| Trial | Design | N | Result | Source | ID |
|---|---|---|---|---|---|
| STEP 1 | RCT, 68 weeks, placebo-controlled | 1,961 | Mean weight change about -14.9% vs -2.4% placebo | N Engl J Med 2021 | NCT03548935 · PMID 33567185 · DOI |
| STEP 3 | RCT, 68 weeks | 611 | About -16.0% with drug + IBT vs -5.7% placebo + IBT | JAMA 2021 | NCT03611582 · PMID 33625476 · DOI |
| STEP 4 | RCT withdrawal design, to week 68 | 803 | Continuing lost further weight; switching to placebo regained substantial weight | JAMA 2021 | NCT03548987 · PMID 33755728 · DOI |
| SELECT | RCT, CV outcomes | 17,604 | About 20% reduction in major adverse cardiovascular events | N Engl J Med 2023 | NCT03574597 · PMID 37952131 · DOI |
| SUSTAIN-6 | RCT, CV outcomes | 3,297 | Reduced CV events vs placebo in type 2 diabetes | N Engl J Med 2016 | NCT01720446 · PMID 27633186 · DOI |
| OASIS 1 | RCT, 68 weeks | 667 | About -15.1% vs -2.4% placebo with the approved oral formulation | Lancet 2023 | NCT05035095 · PMID 37385278 · DOI |
Machine-readable: studies.json, studies.csv. All nine trials carry verified NCT, PMID, and DOI identifiers.
What the evidence shows
- Approved semaglutide at labeled doses produces clinically meaningful weight loss in randomized trials.
- Stopping treatment is associated with weight regain in withdrawal-design trials.
What the evidence does not show
- That a compounded semaglutide microdose reproduces these results — it was never studied.
- That less-frequent or below-label dosing maintains the trial outcomes.
- That a compounded oral/sublingual semaglutide shares the approved product's evidence.
What remains unknown
There is no randomized evidence that a deliberate semaglutide microdose delivers meaningful weight loss, that compounded semaglutide matches the approved product's pharmacokinetics, or that any below-label maintenance strategy preserves the trial results. These are gaps, and this page marks them as gaps rather than filling them with extrapolation.
Frequently asked questions
Is there evidence semaglutide microdosing works?
No direct randomized evidence. The robust data are for approved semaglutide at studied doses; a deliberate microdose's weight-management benefit is unproven.
How much weight did people lose on semaglutide in trials?
About 14.9% mean weight loss in STEP 1 at the approved dose, versus roughly 2.4% on placebo.
Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.